Comparative Pharmacology
Head-to-head clinical analysis: PROCAINAMIDE HYDROCHLORIDE versus QUINATIME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROCAINAMIDE HYDROCHLORIDE versus QUINATIME.
PROCAINAMIDE HYDROCHLORIDE vs QUINATIME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class Ia antiarrhythmic agent; blocks sodium channels, slowing conduction velocity and prolonging refractory period in atrial and ventricular myocardium.
Quinine acts by interfering with the parasite's ability to break down hemoglobin, leading to accumulation of toxic heme and parasite death. It also inhibits nucleic acid and protein synthesis in the parasite.
Oral: 250-500 mg every 3-6 hours. IV: Loading dose 15-18 mg/kg infused over 25-30 minutes, then maintenance infusion 1-4 mg/min. Maximum total daily dose: 4 g.
600 mg (base) orally every 8 hours for 7 days; or 10 mg/kg (base) intravenously loading dose over 1 hour, then 0.02 mg/kg/min continuous infusion for 3 days, then switch to oral.
None Documented
None Documented
Terminal elimination half-life: 2.5-5 hours (normal renal function); prolonged to 11-20 hours in renal impairment (e.g., CrCl <30 mL/min); clinical context: requires dosing adjustment in renal failure; NAPA half-life: 6-8 hours (normal), up to 40 hours in renal failure.
Terminal elimination half-life 10-12 hours in healthy adults; prolonged in hepatic impairment.
Renal: ~50-60% unchanged via glomerular filtration and tubular secretion; hepatic metabolism to N-acetylprocainamide (NAPA, active) accounts for ~15-30% of dose, further eliminated renally; biliary/fecal: negligible (<5%).
Renal: ~20% unchanged; hepatic metabolism (CYP3A4) major route; biliary/fecal: ~80% as metabolites.
Category A/B
Category C
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)